Hulun Li

Hulun Li

Auto-generated profile, based on publicly available information

Hulun Li

Department of Neurobiology, Harbin Medical University, Heilongjiang Provincial Key Laboratory of Neurobiology, 157 Bao Jian Road, Harbin 150081, China; Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2009 in Immunology
Verified
Journal Article
Open access
PDF file
LMLili Mu
Lili Mu
BSBo Sun
Bo Sun
QKQingfei Kong
Qingfei Kong
JWJinghua Wang
Jinghua Wang
GWGuangyou Wang
Guangyou Wang
HLHulun Li
Hulun Li
Summary: Experimental autoimmune myasthenia gravis (EAMG), an animal model of myasthenia gravis (MG), is a rare organ‐specific autoimmune disease targeting the autoantigen nicotinic acetylcholine receptor (AChR). We show here that the balance of T helper type 1 (Th1), Th2, Th17 and regulatory T (Treg) subsets of CD4+ helper T cells were redistributed during the development of EAMG and that the interleukin‐17 (IL‐17) cytokine is involved in this disease. The ratio of Th17 cells changed most notably with disease progression accompanied by an up‐regulated level of IL‐17. Moreover, the proliferative ability of AChR peptide‐specific T cells and the anti‐AChR antibody‐secreting cells increased when stimulated by IL‐17 in vitro. These findings suggested that the disequilibrium of the CD4+ helper T‐cell subsets could promote the development of EAMG, and the pathogenic mechanism by which Th17 cells drives autoimmune responses by secreting cytokine IL‐17 provides a new target for myasthenia gravis therapy.

29 October 2008 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
QWQ. Wang
Q. Wang
BSB. Sun
B. Sun
DWD. Wang
D. Wang
YJY. Ji
Y. Ji
QKQ. Kong
Q. Kong
HLH. Li
H. Li
Bone mesenchymal stem cells (BMSC) are attractive not only in regenerative medicine, but also for the treatment of autoimmune diseases and graft‐versus‐host disease. BMSC also play a role in enabling alloantigen tolerance. An in‐depth mechanistic understanding of this phenomenon of tolerance could lead to novel cell‐based therapies for autoimmune disease. We demonstrate here that co‐culture of mature dendritic cells (DC) with BMSC in a transwell system (BMSC‐DC) downregulated expression of the maturation marker, CD83 and CD80/86 co‐stimulatory molecules on DC, while increasing their endocytic activity. This resulted in defective antigen presentation and co‐stimulatory capacity of mature DC. Functionally, BMSC‐DC have impaired T‐cell stimulatory activity in a mixed lymphocyte reaction and orchestrate a shift from predominantly pro‐inflammatory T‐helper (Th)‐1 to anti‐inflammatory Th2 cells. While the expression of MHC II, CD80 and CD86 were upregulated on BMSC co‐cultured with DC, these BMSC lacked the ability to stimulate T‐cell proliferation. Taken together, these data suggest that the interaction between BMSC and DC modulates the immunoregulatory function of these cells in a coordinated manner, effectively skewing the immune response towards T‐cell tolerance.

27 October 2011 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
YLYing Li
Ying Li
ZCZhen Yuan Cao
Zhen Yuan Cao
BSBo Sun
Bo Sun
GWGuang You Wang
Guang You Wang
ZFZheng Fu
Zheng Fu
HLHu Lun Li
Hu Lun Li
The relationship between IL-17A and cancer, whether beneficial or antagonistic, continues to be a controversial issue. In this study, effects of IL-17A on lung adenocarcinoma were investigated using lung cancer cell lines, 95D and 95C. In the presence or absence of IL-17A, cell proliferation and VEGF secretion were detected. Effects of IL-17A on capillary networks and process of angiogenesis were also evaluated. In vivo, the level of IL-17A was assayed in the serum of lung adenocarcinoma patients. At the same time, slices of adenocarcinoma tissue were analyzed for expression of IL-17A, its receptor (IL-17RA), VEGF, CD4+-IL-17A+ cells and CD8+-IL-17A+ cells by immunohistochemistry and immunofluorescence assays. IL-17A did not have effect on the proliferation of 95D or 95C cells, however, the elevated expression of VEGF in supernatant of 95D or 95C cells was found to be IL-17A concentration-dependent. Supernatants from 95D or 95C cells treated with IL-17A could obviously facilitate angiogenesis, compared with IL-17A absence group (P < 0.01). Higher levels of IL-17A were detected in serum of patients with lung adenocarcinoma than healthy controls (P < 0.001). Higher positive expressions of IL-17A, IL-17RA and VEGF were confirmed in lung adenocarcinoma lesion tissues compared to pericancerous normal tissues (P < 0.001). Tnc17 cells, as well as Th17 cells were found in adenocarcinoma tissue, indicating a potential role of these cells in disease. In summary, IL-17A might affect lung adenocarcinoma by promoting angiogenesis, while the role of Tnc17 cells or Th17 cells remains to be elucidated.

12 March 2009 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
QKQing‐Fei Kong
Qing‐Fei Kong
BSBo Sun
Bo Sun
GWGuang‐You Wang
Guang‐You Wang
DZDong‐Xu Zhai
Dong‐Xu Zhai
LMLi‐Li Mu
Li‐Li Mu
HLHu‐Lun Li
Hu‐Lun Li
In addition to their capacity to differentiate, BM stromal cells (BMSC) have immunosuppressive qualities that make them strong candidates for use in cell therapy against human autoimmune diseases. We studied the immunoregulatory activities of BMSC on experimental autoimmune myasthenia gravis (EAMG) in vitro and in vivo. Intravenous administration of syngenic BMSC to EAMG‐model rats on the day of their second immunization was effective in ameliorating the pathological features of the disease. In vitro, the proliferative ability of T cells or B cells from EAMG rats was inhibited when they were cocultured with BMSC at proper ratios. This inhibitory effect was at least partially dependent on the secretion of IDO. We also determined that the development of EAMG is accompanied by an imbalance among the Th1, Th2, Th17, and Treg cell subsets, and that this can be corrected by the administration of BMSC, which leads to an increase of Th2 (IL‐4) and Treg (Foxp3) cells, and a reduction of Th1 (IFN‐γ) and Th17 (IL‐17) cells, through an IDO‐dependent mechanism. These results provide further insights into the pathogenesis of MG, EAMG, and other immune‐mediated diseases, and support a potential role for BMSC in their treatment.

1 October 2012 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
YSYanyan Sun
Yanyan Sun
TZTianhua Zhang
Tianhua Zhang
BWBeidi Wang
Beidi Wang
HLHulun Li
Hulun Li
PLPeiling Li
Peiling Li
Tannic acid (TA) has been associated with anticancer functions in multiple tumor types both in vitro and in vivo. However, its effect on ovarian carcinoma cells has not been investigated, and its underlying anticancer mechanism(s) remain unclear. In this study, the effects of TA alone and in combination with cisplatin were evaluated using ovarian carcinoma cell lines. Combined treatment with TA and cisplatin was found to induce apoptosis and increase DNA damage in the cisplatin-resistant (SKOV-3 CDDP/R) and cisplatin-sensitive (SKOV-3) human ovarian carcinoma cell lines, respectively. TA was also found to enhance the toxicity of cisplatin in ovarian carcinoma cells associated with the inhibition of poly(ADP-ribose) glycohydrolase (PARG) expression, increase the accumulation of poly(ADP-ribose) (pADPr), following the release of apoptosis-inducing factor, and the activation of caspase-3. In conclusion, as a PARG inhibitor, TA showed anticancer activity and increased the sensitivity of SKOV-3 cells and SKOV-3 CDDP/R cell lines to cisplatin.

26 April 2012 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
NLNa Li
Na Li
LMLili Mu
Lili Mu
JWJinghua Wang
Jinghua Wang
JZJia Zhang
Jia Zhang
XXXiaoli Xie
Xiaoli Xie
HLHulun Li
Hulun Li
The adenosineA2Areceptor (A2AR) is the major cellular adenosine receptor commonly associated with immunosuppression. Here, we investigated whetherA2ARactivation holds the potential for impacting the severity of experimental autoimmune myasthenia gravis (EAMG) induced following immunization ofLewis rats with the acetylcholine receptor (AChR)R97–116 peptide. This report demonstrates reducedA2ARexpression by bothTcells andBcells residing in spleen and lymph nodes followingEAMGinduction.A2ARstimulation inhibited anti‐AChRantibody production and proliferation ofAChR‐specific lymphocytes in vitro. Inhibition was blocked with theA2ARantagonists or protein kinaseAinhibitor. We also determined that the development ofEAMGwas accompanied by aT‐helper cell imbalance that could be restored followingA2ARstimulation that resulted in increasedTreg cell levels and a reduction inTh1‐,Th2‐, andTh17‐cell subtypes. AnEAMG‐preventive treatment regimen was established that consisted of (2‐(p‐(2‐carbonylethyl)phenylethylamino)‐5‐N‐ethylcarboxamidoadenosine) (CGS21680;A2ARagonist) administration 1 day prior toEAMGinduction. Administration ofCGS21680 29 days postEAMGinduction (therapeutic treatment) also ameliorated disease severity. We conclude thatA2ARagonists may represent a new class of compounds that can be developed for use in the treatment of myasthenia gravis or otherT‐cell‐ andB‐cell‐mediated autoimmune diseases.